BIZZARI JEAN-PIERRE 4

What Happened

• Jean-Pierre Bizzari, a director of Aprea Therapeutics (APRE), received equity awards on June 16, 2026 consisting of 3,135 shares and 12,555 derivative units, both recorded at $0.00 purchase price (totaling 15,690 units). These are grants/awards (transaction code A), not open‑market purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date(s): June 16, 2026. Form filed: June 17, 2026 (timely; Form 4 is typically due within 2 business days).
• Reported prices/values: $0.00 per share for both entries (standard for RSU/award grants); reported monetary value = $0.
• Vesting/settlement: Footnote F1—these represent restricted stock units (RSUs) granted June 16, 2026 that will vest and be settled in common stock on June 16, 2027, subject to continued board service and possible acceleration. Footnote F2—the derivative/option vests in full on June 16, 2027, subject to continued service and possible acceleration.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction type: Award/Grant (A). These are equity compensation awards, not sales or purchases.

Context

• RSUs and similar derivative awards are compensation that convert into common shares only after vesting; they are not immediate indicators of buying or selling activity. Because the grant price is $0, the economic value depends on Aprea’s stock price at vesting.
• This filing shows director compensation and is routine for corporate governance/retention; it does not reflect an open‑market purchase (which some investors view as a stronger bullish signal).